The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog

Amy K. Harker-Murray, A. Jamil Tajik, Fumiobu Ishikura, Donna Meyer, John C Jr. Burnett, Margaret May Redfield

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Background: Coenzyme Q10 (CoQ10) is essential for ATP generation and has antioxidant properties. Decreased CoQ10 levels have been reported in human heart failure (CHF), but it remains unclear if this is a conserved feature of CHF. The objective of the study was to determine if tachycardia-induced CHF in the dog is associated with reduced CoQ10 levels. Furthermore, it was hypothesized that CoQ10 supplementation may improve CHF severity by preventing CoQ10 deficiency (if present) or via antioxidant effects. Methods and Results: Serum and myocardial levels of CoQ10 were examined in normal dogs (n = 6), dogs with CHF (control, n = 5), and dogs with CHF treated with CoQ10 (CoQ10; 10 mg/kg/day, n = 5). Serum CoQ10 levels did not change with CHF in control dogs, and myocardial levels were similar to those of normal dogs. CoQ10 therapy increased serum but not myocardial levels of CoQ10. In early CHF, CoQ10-treated dogs had lower filling pressures, and, in severe CHF, CoQ10-treated dogs had less hypertrophy as compared with untreated dogs. Other indices of CHF severity were similar in control and CoQ10-treated dogs. Conclusion: These data indicate that CoQ10 deficiency is not present in this model of CHF. Although dramatic effects on hemodynamics were not observed, CoQ10 supplementation did appear to attenuate the hypertrophic response associated with CHF.

Original languageEnglish (US)
Pages (from-to)233-242
Number of pages10
JournalJournal of Cardiac Failure
Volume6
Issue number3
DOIs
StatePublished - 2000

Fingerprint

coenzyme Q10
Investigational Therapies
Heart Failure
Dogs

Keywords

  • Antioxidant
  • Cardiomyopathy
  • Enzymes
  • Hormones

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. / Harker-Murray, Amy K.; Tajik, A. Jamil; Ishikura, Fumiobu; Meyer, Donna; Burnett, John C Jr.; Redfield, Margaret May.

In: Journal of Cardiac Failure, Vol. 6, No. 3, 2000, p. 233-242.

Research output: Contribution to journalArticle

@article{e5a3368581794438a3354af3e7e24cb2,
title = "The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog",
abstract = "Background: Coenzyme Q10 (CoQ10) is essential for ATP generation and has antioxidant properties. Decreased CoQ10 levels have been reported in human heart failure (CHF), but it remains unclear if this is a conserved feature of CHF. The objective of the study was to determine if tachycardia-induced CHF in the dog is associated with reduced CoQ10 levels. Furthermore, it was hypothesized that CoQ10 supplementation may improve CHF severity by preventing CoQ10 deficiency (if present) or via antioxidant effects. Methods and Results: Serum and myocardial levels of CoQ10 were examined in normal dogs (n = 6), dogs with CHF (control, n = 5), and dogs with CHF treated with CoQ10 (CoQ10; 10 mg/kg/day, n = 5). Serum CoQ10 levels did not change with CHF in control dogs, and myocardial levels were similar to those of normal dogs. CoQ10 therapy increased serum but not myocardial levels of CoQ10. In early CHF, CoQ10-treated dogs had lower filling pressures, and, in severe CHF, CoQ10-treated dogs had less hypertrophy as compared with untreated dogs. Other indices of CHF severity were similar in control and CoQ10-treated dogs. Conclusion: These data indicate that CoQ10 deficiency is not present in this model of CHF. Although dramatic effects on hemodynamics were not observed, CoQ10 supplementation did appear to attenuate the hypertrophic response associated with CHF.",
keywords = "Antioxidant, Cardiomyopathy, Enzymes, Hormones",
author = "Harker-Murray, {Amy K.} and Tajik, {A. Jamil} and Fumiobu Ishikura and Donna Meyer and Burnett, {John C Jr.} and Redfield, {Margaret May}",
year = "2000",
doi = "10.1054/jcaf.2000.8839",
language = "English (US)",
volume = "6",
pages = "233--242",
journal = "Journal of Cardiac Failure",
issn = "1071-9164",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog

AU - Harker-Murray, Amy K.

AU - Tajik, A. Jamil

AU - Ishikura, Fumiobu

AU - Meyer, Donna

AU - Burnett, John C Jr.

AU - Redfield, Margaret May

PY - 2000

Y1 - 2000

N2 - Background: Coenzyme Q10 (CoQ10) is essential for ATP generation and has antioxidant properties. Decreased CoQ10 levels have been reported in human heart failure (CHF), but it remains unclear if this is a conserved feature of CHF. The objective of the study was to determine if tachycardia-induced CHF in the dog is associated with reduced CoQ10 levels. Furthermore, it was hypothesized that CoQ10 supplementation may improve CHF severity by preventing CoQ10 deficiency (if present) or via antioxidant effects. Methods and Results: Serum and myocardial levels of CoQ10 were examined in normal dogs (n = 6), dogs with CHF (control, n = 5), and dogs with CHF treated with CoQ10 (CoQ10; 10 mg/kg/day, n = 5). Serum CoQ10 levels did not change with CHF in control dogs, and myocardial levels were similar to those of normal dogs. CoQ10 therapy increased serum but not myocardial levels of CoQ10. In early CHF, CoQ10-treated dogs had lower filling pressures, and, in severe CHF, CoQ10-treated dogs had less hypertrophy as compared with untreated dogs. Other indices of CHF severity were similar in control and CoQ10-treated dogs. Conclusion: These data indicate that CoQ10 deficiency is not present in this model of CHF. Although dramatic effects on hemodynamics were not observed, CoQ10 supplementation did appear to attenuate the hypertrophic response associated with CHF.

AB - Background: Coenzyme Q10 (CoQ10) is essential for ATP generation and has antioxidant properties. Decreased CoQ10 levels have been reported in human heart failure (CHF), but it remains unclear if this is a conserved feature of CHF. The objective of the study was to determine if tachycardia-induced CHF in the dog is associated with reduced CoQ10 levels. Furthermore, it was hypothesized that CoQ10 supplementation may improve CHF severity by preventing CoQ10 deficiency (if present) or via antioxidant effects. Methods and Results: Serum and myocardial levels of CoQ10 were examined in normal dogs (n = 6), dogs with CHF (control, n = 5), and dogs with CHF treated with CoQ10 (CoQ10; 10 mg/kg/day, n = 5). Serum CoQ10 levels did not change with CHF in control dogs, and myocardial levels were similar to those of normal dogs. CoQ10 therapy increased serum but not myocardial levels of CoQ10. In early CHF, CoQ10-treated dogs had lower filling pressures, and, in severe CHF, CoQ10-treated dogs had less hypertrophy as compared with untreated dogs. Other indices of CHF severity were similar in control and CoQ10-treated dogs. Conclusion: These data indicate that CoQ10 deficiency is not present in this model of CHF. Although dramatic effects on hemodynamics were not observed, CoQ10 supplementation did appear to attenuate the hypertrophic response associated with CHF.

KW - Antioxidant

KW - Cardiomyopathy

KW - Enzymes

KW - Hormones

UR - http://www.scopus.com/inward/record.url?scp=0033626251&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033626251&partnerID=8YFLogxK

U2 - 10.1054/jcaf.2000.8839

DO - 10.1054/jcaf.2000.8839

M3 - Article

VL - 6

SP - 233

EP - 242

JO - Journal of Cardiac Failure

JF - Journal of Cardiac Failure

SN - 1071-9164

IS - 3

ER -